Novartis is acquiring biopharmaceutical company Tourmaline Bio for $1.4 billion to boost its cardiovascular pipeline.
Tourmaline develops pacibekitug, a drug used to treat atherosclerotic cardiovascular disease, according to a Sept. 9 news release from Novartis.
Novartis said the drug is in advanced phase 2 clinical trials and works to combat residual inflammatory risk more effectively than current therapies. The drug is being added to the drugmaker’s existing cardiovascular therapy portfolio, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
